^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TMB-H

i
Other names: TMB | Tumor Mutational Burden
Related biomarkers:
Related tests:
8ms
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • TMB-H • PD-L1 overexpression
|
Imfinzi (durvalumab)
10ms
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ACVR2A (Activin A Receptor Type 2A)
|
TMB-H • MSI-H/dMMR
10ms
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ACVR2A (Activin A Receptor Type 2A)
|
TMB-H • MSI-H/dMMR
11ms
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset) • MRE11A (MRE11 homolog, double strand break repair nuclease)
|
TMB-H • HER-2 amplification • MRE11A mutation
11ms
Clinical • Clinical data • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase)
|
BRCA2 mutation • TMB-H • ATM mutation • BRCA2 mutation + ATM mutation
11ms
Clinical • Clinical data • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase)
|
BRCA2 mutation • TMB-H • ATM mutation • BRCA2 mutation + ATM mutation
11ms
IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • STK11 (Serine/threonine kinase 11) • ARID2 (AT-Rich Interaction Domain 2)
|
PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • TMB-H • ATM mutation • STK11 mutation • KRAS mutation + STK11 mutation + TP53 mutation • KRAS expression
12ms
Clinical • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden)
|
TMB-H
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
1year
Clinical • IO biomarker
|
TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • mTOR (Mechanistic target of rapamycin kinase) • RASA1 (RAS P21 Protein Activator 1) • SMAD2 (SMAD Family Member 2)
|
TMB-H • MTOR mutation
1year
Clinical • Metastases
|
TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
TMB-H